Страна: Канада
мова: англійська
Джерело: Health Canada
CLARITHROMYCIN
MANTRA PHARMA INC
J01FA09
CLARITHROMYCIN
250MG
TABLET
CLARITHROMYCIN 250MG
ORAL
100
Prescription
OTHER MACROLIDES
Active ingredient group (AIG) number: 0123752001; AHFS:
CANCELLED POST MARKET
2023-07-13
_M-CLARITHROMYCIN (Clarithromycin tablets), Product Monograph _ _Page 1 of 69 _ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR M-CLARITHROMYCIN Clarithromycin Tablets Tablets, 250 mg and 500 mg, Oral USP Antibiotic NOTE: WHEN USED IN COMBINATION WITH ACID ANTISECRETORY DRUGS AND OTHER ANTIMICROBIALS FOR THE ERADICATION OF _HELICOBACTER PYLORI_, THE PRODUCT MONOGRAPH FOR THOSE AGENTS SHOULD BE CONSULTED. Mantra Pharma Inc., 9150 Leduc Blvd., Suite 201 Brossard, Quebec J4Y 0E3 Date of Initial Authorization: January 03, 2018 _ _ Date of revision: DEC 15, 2022 Submission Control Number: 270062 _ _ _M-CLARITHROMYCIN (Clarithromycin tablets), Product Monograph _ _Page 2 of 69 _ RECENT MAJOR LABEL CHANGES 2 CONTRAINDICATIONS 12/2022 7 WARNINGS AND PRECAUTIONS; 7.1.1 Pregnant Women; 7.1.2 Breast- feeding 12/2022 TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED. RECENT MAJOR LABEL CHANGES ............................................................................................ 2 TABLE OF CONTENTS .............................................................................................................. 2 PART I: HEALTH PROFESSIONAL INFORMATION ...................................................................... 4 1 INDICATIONS .............................................................................................................. 4 1.1 Pediatrics ................................................................................................................... 5 1.2 Geriatrics ................................................................................................................... 5 2 CONTRAINDICATIONS ................................................................................................. 5 3 SERIOUS WARNINGS AND PRECAUTIONS BOX ............................................................. 6 4 DOSAGE AND ADMINISTRATION ................................................................................. 6 4.1 Dosing C Прочитайте повний документ